Next Article in Journal
Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection
Next Article in Special Issue
Role of Lymphocytic Choriomeningitis Virus (LCMV) in Understanding Viral Immunology: Past, Present and Future
Previous Article in Journal
MicroRNAs, Hepatitis C Virus, and HCV/HIV-1 Co-Infection: New Insights in Pathogenesis and Therapy
Previous Article in Special Issue
Junín Virus Pathogenesis and Virus Replication
Article Menu

Export Article

Open AccessReview

Advanced Vaccine Candidates for Lassa Fever

Department of Pharmacology and Toxicology, School of Medicine, and the Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Kentucky, USA
Viruses 2012, 4(11), 2514-2557;
Received: 27 September 2012 / Revised: 20 October 2012 / Accepted: 22 October 2012 / Published: 29 October 2012
(This article belongs to the Special Issue Arenaviruses)
PDF [1116 KB, uploaded 12 May 2015]


Lassa virus (LASV) is the most prominent human pathogen of the Arenaviridae. The virus is transmitted to humans by a rodent reservoir, Mastomys natalensis, and is capable of causing lethal Lassa Fever (LF). LASV has the highest human impact of any of the viral hemorrhagic fevers (with the exception of Dengue Fever) with an estimated several hundred thousand infections annually, resulting in thousands of deaths in Western Africa. The sizeable disease burden, numerous imported cases of LF in non-endemic countries, and the possibility that LASV can be used as an agent of biological warfare make a strong case for vaccine development. Presently there is no licensed vaccine against LF or approved treatment. Recently, several promising vaccine candidates have been developed which can potentially target different groups at risk. The purpose of this manuscript is to review the LASV pathogenesis and immune mechanisms involved in protection. The current status of pre-clinical development of the advanced vaccine candidates that have been tested in non-human primates will be discussed. Major scientific, manufacturing, and regulatory challenges will also be considered. View Full-Text
Keywords: Lassa fever; pathogenesis; vaccines; efficacy in primates Lassa fever; pathogenesis; vaccines; efficacy in primates

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Lukashevich, I.S. Advanced Vaccine Candidates for Lassa Fever. Viruses 2012, 4, 2514-2557.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top